KNect365 is part of the Knowledge and Networking Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.


Celyad VP talks IP issues, development timelines for CAR-T therapies

Georges Rawadi, VP of business development and intellectual property at Celyad, discusses the company's CAR-T pipeline, recently resolved IP issues and the firm's strategy for future clinical development. At the recent BIO-Europe Spring partnering meeting in Barcelona, Rawadi told Scrip more about how Celyad's technology will compete with other treatments coming through the immuno-oncology development pipeline and the next big milestones for the business.

Interviewer: Lucie Ellis – Senior Writer, Pharma Intelligence In Vivo/Pink Sheet/Scrip
Interviewee: Georges Rawadi – VP Business Development and IP, Celyad

Get the latest news as it happens.